RGPD6

Across TCGA pan-cancer cohorts, RGPD6 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated RGPD6 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RGPD6 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RGPD6 expression acts as an unfavorable survival marker, although some lineages such as SKCM and THYM show a favorable association.

STAD, OV, and KIRP are the cancer types where RGPD6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	II,III,IV	0.212	0.481	.001	77	view →
OV	DFS	Tertile	III,IV	0.423	0.577	.002	74	view →
KIRP	OS	Tertile	IV	0.037	0.429	.017	51	view →
ACC	DFS	Tertile	All	0.209	0.758	<.001	50	view →
PAAD	OS	Median	III,IV	0.629	1.000	.022	24	view →
KIRC	DFS	Tertile	All	0.425	0.706	.006	24	view →
READ	DFS	Quartile	IV	0.190	0.760	<.001	24	view →
SKCM	OS	Median	III,IV	0.575	0.273	.001	19	view →
GBM	DFS	Tertile	All	0.141	0.285	.006	15	view →
CESC	DFS	Tertile	II,III,IV	0.188	0.708	.006	12	view →
UCEC	DFS	Quartile	IV	0.136	0.729	<.001	12	view →
LIHC	DFS	Tertile	All	0.293	0.473	.021	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

RGPD6–STAD (DFS)

Open the STAD breakdown →